Middle East And Africa Branded Generics Market
Market Size in USD Billion
CAGR :
% 
USD
20.89 Billion
USD
34.25 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 20.89 Billion |
 Market Size (Forecast Year) |
USD 34.25 Billion |
 CAGR |
% |
| Major Markets Players |
|
Middle East and Africa Branded Generics Market Segmentation, By Drug Class (Anti-Hypertensive, Hormones, Antimetabolites, Lipid Lowering Drugs, Anti-Epileptics, Alkylating Agents, Anti-Depressants, Anti-Psychotics, Others), By Application (Cardiovascular Diseases, Pain Management and Anti-inflammatory, Oncology, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology, Others), By Route of Administration (Oral, Injectable, Topical Administration, Others), By Product Type (Value-Added Branded Generics, Trade Named Generics), By Patient Demographics (Adult, Geriatric, Pediatric), By End User (Hospitals, Clinics, Homecare, Academic & Research Institutes, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Direct Tenders, Others) - Industry Trends and Forecast to 2032
Middle East and Africa Branded Generics Market Size
- The Middle East and Africa Branded Generics Market was valued at USD 20.89 Billion in 2024 and is expected to reach USD 34.25 Billion by 2032
- During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 6.4%, primarily driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and the demand for affordable, high-quality medication in both developed and emerging markets
- This growth is further fueled by patent expirations of originator drugs, government policies supporting cost-effective treatments, expansion of healthcare access in emerging economies, and rising adoption of digital health and e-pharmacy channels. Continuous innovations in drug formulations, improved patient adherence strategies, and expanding branded generics portfolios by leading pharmaceutical companies are also expected to accelerate market expansion globally
Middle East and Africa Branded Generics Market Analysis
- The Middle East and Africa Branded Generics Market is experiencing robust growth, driven by rising demand for cost-effective, high-quality pharmaceutical products that combine the affordability of generics with brand recognition. Branded Generics play a vital role in improving patient adherence, expanding access to essential medications, and providing revenue opportunities for pharmaceutical companies in both emerging and developed markets. The market faces challenges including regulatory variations across countries, pricing pressures, and the need for ongoing innovation to maintain brand loyalty.
- The chronic disease management, oncology, cardiovascular, and infectious disease therapy segments are key growth drivers. Increasing prevalence of non-communicable diseases, rising healthcare awareness, and expanding access to healthcare in emerging economies are boosting demand for Branded Generics. In addition, the growing adoption of biosimilars and specialty generics is shaping market dynamics, offering alternatives to costly originator drugs while maintaining efficacy and safety. Pharmaceutical companies are leveraging marketing strategies, patient education, and strategic partnerships to enhance the uptake of Branded Generics.
- Saudi Arabia dominates the market, and United Arab Emirates is the fastest growing country, due to the region’s well-established generic drug manufacturing capabilities, favorable government policies, and increasing healthcare expenditure.
- The anti-hypertensive segment is expected to dominate the market with 30.52% market share market share, driven by patient preference for convenient dosing, cost-effectiveness, and broad applicability across therapeutic areas.
Report Scope and Middle East and Africa Branded Generics Market Segmentation
|
Attributes |
Middle East and Africa Branded Generics Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Middle East and Africa
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Middle East and Africa Branded Generics Market Trends
“Rising Demand for Affordable, High-Quality Medicines Drives Middle East and Africa Branded Generics Market Growth”
- Increasing healthcare costs, aging populations, and the rising prevalence of chronic and lifestyle-related diseases are driving Middle East and Africa demand for affordable yet high-quality medications, supporting the growth of branded generics. Branded generics provide a cost-effective alternative to originator drugs while maintaining high standards of efficacy and safety, making them essential in both developed and emerging markets
- Governments and healthcare payers are actively promoting the use of branded generics through policies, reimbursement frameworks, and generic substitution programs to contain healthcare expenditure, expand access to treatment, and improve patient adherence. These measures are boosting market adoption across multiple therapeutic areas, including cardiovascular, diabetes, oncology, and central nervous system disorders
- For instance, in March 2024, the U.S. FDA approved multiple new branded generic formulations for high-demand therapeutic categories such as diabetes and hypertension, demonstrating the increasing pipeline activity and regulatory support for cost-effective alternatives to branded drugs. This illustrates the ongoing expansion of the Middle East and Africa Branded Generics Market in response to patient and healthcare system needs
- Emerging economies, particularly in Saudi Arabia and Latin America, are witnessing accelerated uptake of branded generics due to expanding healthcare infrastructure, rising middle-class populations, and government initiatives aimed at improving treatment accessibility. Companies are scaling up local production, investing in R&D, and enhancing distribution networks to meet growing demand in these regions
- As Middle East and Africa healthcare systems continue to emphasize affordability, accessibility, and treatment adherence, the role of branded generics will become increasingly critical in ensuring sustainable healthcare delivery while driving innovation in manufacturing, packaging, and patient-focused drug development.
Middle East and Africa Branded Generics Market Dynamics
Driver
“Patent Expirations Of Blockbuster Drugs”
- The impending patent expirations of blockbuster drugs are among the most powerful structural drivers of the Middle East and Africa Branded Generics Market's expansion. When a high-revenue innovator drug loses exclusivity, it opens the door for generic and biosimilar manufacturers to introduce competing versions, eroding the innovator’s market share and redirecting demand toward lower-cost alternatives
- This “patent cliff” triggers a cascade of downstream effects: manufacturers rush to file Abbreviated New Drug Applications (ANDAs) or biosimilar applications, regulatory authorities expedite review, payers increasingly favor generics, and patients gain access to more affordable branded generics
- Over the past decade, the wave of lost exclusivity across large therapeutics has created recurring windows of chance for generic incumbents and new entrants, reshaping pricing dynamics, encouraging consolidation in generics manufacturing, and accelerating geographic expansion into emerging markets. Indeed, the scale of revenues at stake from expired patents often provides the economic justification for investment in complex generics and biosimilars
- . Importantly, the timing and predictability of patent cliffs afford strategic planning windows for generics firms to anticipate launches, invest in development pipelines, form alliances, and pre-file regulatory dossiers ahead of exclusivity loss
- Consequently, the branded generics sector becomes a cyclical frontier of competitive driver, intimately tied to the blockbuster patent expirations
Restraint/Challenge
“Patent Litigation And Intellectual Property Risks”
- Patent litigation and intellectual property risks pose a significant restraint on the Middle East and Africa Branded Generics Market. The complexity and duration of patent disputes can delay the entry of generic alternatives, hindering market competition and keeping drug prices high.
- These legal battles often involve multiple layers of patent claims, including method-of-use patents and secondary patents, which can extend the exclusivity period of branded drugs beyond their original patent expiration.
- Additionally, the financial burden of defending against patent infringement lawsuits can deter generic manufacturers, especially smaller firms, from entering the market. The evolving landscape of patent laws and the strategic use of patent portfolios by originator companies further complicate market dynamics, potentially leading to a branded-generic market globally
- For instance, In October 2025, The Economic Times reported that Hyderabad-based Natco Pharma won a patent dispute against Swiss pharmaceutical company Roche concerning the drug Risdiplam, used to treat spinal muscular atrophy
- These legal and financial barriers affect both manufacturer profitability and patient access to affordable medicines. Overall, patent litigation and IP risks remain key restraints that influence competition and growth in the Middle East and Africa Branded Generics Market
Middle East and Africa Branded Generics Market Scope
The Middle East and Africa Branded Generics Market is segmented into seven notable segments which are based on drug class, application, route of administration, product type, patient demographics, end user, and distribution channel.
• By Drug Class
On the basis of drug class, the Middle East and Africa Branded Generics Market is segmented into anti-hypertensive, hormones, antimetabolites, lipid lowering drugs, anti-epileptics, alkylating agents, anti-depressants, anti-psychotics, and others. In 2025, the anti-hypertensive segment is expected to dominate the market with 30.52% market share, driven by the rising prevalence of cardiovascular diseases, increasing awareness about hypertension management, and growing preference for cost-effective generic alternatives by patients and healthcare providers.
The anti-hypertensive segment is anticipated to gain traction with a CAGR of 8.0% during the forecast period of 2025 to 2032, driven by continuous innovation in fixed-dose combination therapies, government initiatives promoting affordable medications, and expanding access to healthcare in emerging economies, which collectively boost the adoption of anti-hypertensive branded generics.
• By Application
On the basis of Application, the market is segmented into cardiovascular diseases, pain management and anti-inflammatory, oncology, diabetes, neurology, gastrointestinal diseases, dermatology, and others. In 2025, the cardiovascular diseases segment is expected to dominate the market with 36.62% market share, owing to the rising prevalence of heart-related disorders globally, increasing geriatric population, and growing awareness about preventive cardiovascular care coupled with the availability of cost-effective branded generic medications.
The cardiovascular diseases segment is projected to expand steadily with a CAGR of 7.4%, as healthcare systems in emerging markets enhance access to essential medications, fixed-dose combination therapies gain popularity, and ongoing research and development improve the efficacy and safety profile of branded generics for cardiovascular treatment.
• By Route Of Administration
On the basis of route of administration, the Middle East and Africa Branded Generics Market is segmented into oral, injectable, topical administration, and others. In 2025, the oral segment is expected to dominate the market with 60.45% market share, attributed to the convenience of oral administration, high patient compliance, widespread availability of oral formulations, and cost-effectiveness compared to other routes.
The oral segment is likely to witness accelerated growth of 6.6% during the forecast period, supported by the increasing prevalence of chronic diseases requiring long-term medication, rising preference for self-administered therapies, and the continuous introduction of innovative oral formulations with improved bioavailability and patient-friendly designs.
• By Product Type
On the basis of Product Type, the market is segmented into value-added Branded Generics and trade named generics. In 2025, the value-added Branded Generics segment is expected to dominate the market with a 70.32% market share, driven by their enhanced efficacy, improved safety profiles, patient-centric formulations, and ability to offer differentiated therapeutic benefits over standard generics.
The value-added Branded Generics segment is gaining importance and growing with a CAGR of 6.5% due to rising healthcare provider preference for formulations that improve patient adherence, growing demand for combination therapies, continuous innovation in drug delivery technologies, and the focus on addressing unmet medical needs in chronic and complex disease treatments.
• By Patient Demographics
On the basis of Patient Demographics, the market is segmented into adult, geriatric, and paediatric. In 2025, the adult segment is expected to dominate the market with a 68.75% market share, owing to the higher prevalence of chronic and lifestyle-related diseases such as cardiovascular disorders, diabetes, and hypertension in the adult population, which drives consistent demand for Branded Generics.
The adult segment is expected to grow at a CAGR of 6.5%, driven by increasing healthcare awareness, rising access to affordable medications, the growing middle-class population in emerging economies, and the preference for value-added Branded Generics that offer better efficacy and adherence among adult patients.
• By End User
On the basis of End User, the market is segmented into hospitals, clinics, homecare, academic & research institutes, and others. In 2025, the hospitals segment is expected to dominate the market with a 56.55% market share, driven by the high volume of patient treatments, preference for branded and high-quality generics for critical care, and the centralized procurement practices of hospitals that ensure consistent supply of essential medications.
The hospitals segment is anticipated to record the fastest growth of 6.7% during 2025 to 2032, driven by expansion of hospital infrastructure, increasing number of specialty and multi-specialty hospitals, rising hospital admissions for chronic and acute conditions, and the growing adoption of value-added Branded Generics in inpatient care for improved therapeutic outcomes.
• By Distribution Channel
On the basis of Distribution Channel, the market is segmented into retail pharmacies, hospital pharmacies, direct tenders, and others. In 2025, the retail pharmacies segment is expected to dominate the market with a 57.45% market share, driven by the widespread availability of Branded Generics through retail outlets, consumer preference for convenient access to medications, and the strong presence of pharmacy chains and independent drug stores in both urban and semi-urban areas.
The retail pharmacies segment is anticipated to record the fastest growth of 6.6% during 2025 to 2032, driven by increasing self-medication trends, growing awareness of cost-effective Branded Generics, expansion of pharmacy networks, and government initiatives supporting affordable access to essential medicines through retail channels.
Middle East and Africa Branded Generics Market – Regional Analysis
- Saudi Arabia is expected to dominate the Middle East and Africa Branded Generics Market with the largest revenue share of 28.55% in 2025, driven by strong demand for affordable yet high-quality pharmaceutical products and rising healthcare expenditure across the region.
- The expansion is fueled by increasing government support for healthcare infrastructure, growing chronic disease prevalence, and rising awareness about treatment adherence, all of which drive the adoption of Branded Generics.
- Countries such as India, China, Japan, and South Korea lead the region due to their well-established pharmaceutical manufacturing capabilities, regulatory support for generics, and increasing investment in domestic healthcare production.
- Additionally, favorable policies promoting local drug production, healthcare access, and pharmaceutical exports further accelerate market growth in Saudi Arabia.
Middle East & Africa Middle East and Africa Branded Generics Market Insight
Middle East & Africa represents an emerging growth region for the Middle East and Africa Branded Generics Market, supported by increasing healthcare access, infrastructure expansion, and growing government initiatives to improve treatment affordability. Countries such as Saudi Arabia, UAE, and South Africa are investing in local pharmaceutical production, healthcare modernization, and digital health programs, which are boosting market adoption. While still in a developing phase compared to other regions, rising awareness of cost-effective treatments, improved healthcare coverage, and regulatory reforms are expected to drive steady long-term growth for branded generics across the Middle East & Africa.
Saudi Arabia Middle East and Africa Branded Generics Market Insight
Saudi Arabia holds an important position within Middle East & Africa’s Middle East and Africa Branded Generics Market, supported by its strong healthcare infrastructure, advanced pharmaceutical manufacturing capabilities, and government initiatives encouraging domestic drug production. The country’s focus on chronic disease management, oncology, and cardiovascular therapies is increasing the demand for branded generics. Moreover, strategic partnerships between pharmaceutical companies and research institutions are driving innovation in high-value generics and specialty therapies. France’s growing emphasis on healthcare access, affordability, and treatment adherence further reinforces its significance in Europe’s pharmaceutical landscape.
Egypt Middle East and Africa Branded Generics Market Insight
Egypt is emerging as a growing market within Middle East & Africa’s Branded generics industry, fueled by expanding healthcare coverage, increasing demand for affordable therapies, and rising adoption of chronic disease management solutions. The country’s focus on healthcare modernization, digital health initiatives, and regional pharmaceutical production has accelerated the use of branded generics. Additionally, collaborations between local manufacturers, research institutions, and international pharmaceutical firms are supporting innovation and commercialization of high-quality generic products. Spain’s investments in healthcare infrastructure and patient awareness campaigns are contributing to steady market growth.
South Africa Middle East and Africa Branded Generics Market Insight
South Africa is projected to record the highest CAGR Middle East and Africa during the forecast period, supported by rising healthcare expenditure, rapid industrialization of pharmaceutical manufacturing, and increasing prevalence of chronic and lifestyle-related diseases. Countries such as India, China, and Japan are leading the growth, driven by expanding domestic production capacity, cost-effective drug manufacturing, and supportive regulatory policies. The region’s strong pharmaceutical export capabilities, growing healthcare access, and initiatives for local drug production are further accelerating market growth. Increasing awareness about treatment adherence and demand for high-quality, affordable medications continue to strengthen the region’s dominance in the Middle East and Africa market.
The Major Market Leaders Operating in the Market Are:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris Inc. (U.S.)
- Sandoz Group AG (Switzerland)
- Dr. Reddy’s Laboratories Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Cipla Pharmaceuticals (India)
- Fresenius Kabi (Germany)
- Abbott (U.S.)
- Glenmark Pharmaceuticals (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Lupin Pharmaceuticals (India)
- Emcure Pharmaceuticals (India)
- Bausch Health Companies Inc. (Canada)
- Mankind Pharma (India)
- Jubilant Pharma (India)
- Natco Pharma (India)
- ARISTO Pharmaceuticals Private Limited (India)
- Biocon Limited (India)
- Torrent Pharmaceuticals Ltd. (India)
- Endo, Inc. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- SAGENT Pharmaceuticals (U.S.)
- Panacea Biotec (India)
Latest Developments in Middle East and Africa Branded Generics Market
- In October 2025, The U.S. FDA has approved an expanded indication for UZEDY (risperidone) extended-release injectable suspension. It is now approved for the treatment of schizophrenia in children and adolescents aged 13 to 17 years, in addition to adults. This provides a long-acting treatment option for younger patients managing this chronic condition
- In August 2025, Teva has received U.S. FDA approval for and launched the first generic version of Saxenda (liraglutide) injection. This generic GLP-1 receptor agonist is approved as a weight management tool for adults and pediatric patients, providing a more accessible option for chronic weight management.
- In August 2025, Viatris has received U.S. FDA approval for the first generic version of Iron Sucrose Injection, a medication used to treat iron deficiency anemia. This development provides a more affordable treatment option for patients and healthcare providers in the United States. The approval strengthens Viatris's portfolio of generic injectable medicines and enhances patient access to this critical therapy.
- In April 2025, Viatris has filed supplemental new drug applications with Japan's Ministry of Health, Labour and Welfare seeking approval for EFFEXOR (venlafaxine) for the treatment of Generalized Anxiety Disorder. This regulatory step aims to expand the therapeutic use of this medication in the Japanese market. If approved, it would provide a new treatment option for patients in Japan suffering from this condition.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 PRODUCT VS BRAND OVERVIEW
4.2.1.1 PRODUCT OVERVIEW
4.2.1.2 BRAND OVERVIEW
4.3 CONSUMER BUYING BEHAVIOUR – MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 JOINT VENTURES
4.4.1.2 MERGERS AND ACQUISITIONS
4.4.1.3 LICENSING AND PARTNERSHIP
4.4.1.4 TECHNOLOGY COLLABORATIONS
4.4.1.5 STRATEGIC DIVESTMENTS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES AND MILESTONES
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.4.6 RISK ASSESSMENT AND MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PATENT ANALYSIS – MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
4.5.1 PATENT QUALITY AND STRENGTH
4.5.2 PATENT FAMILIES
4.5.3 LICENSING AND COLLABORATIONS
4.5.4 REGIONAL PATENT LANDSCAPE
4.5.5 IP STRATEGY AND MANAGEMENT
4.6 PRICING ANALYSIS
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIAL SUPPLY
4.7.3 COMPONENT MANUFACTURING AND PROCESSING
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS
4.7.5 DISTRIBUTION AND LOGISTICS
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS)
4.7.7 CONCLUSION
5 REGULATION COVERAGE
5.1 REGULATION COVERAGE (NORTH AMERICA)
5.2 REGULATION COVERAGE (SOUTH AMERICA)
5.3 REGULATION COVERAGE (EUROPE)
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA)
5.5 REGULATION COVERAGE (ASIA-PACIFIC)
5.6 SUPPLY CHAIN ANALYSIS OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
5.6.1 OVERVIEW
5.6.2 LOGISTIC COST SCENARIO
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
5.6.4 CONCLUSION
5.7 TECHNOLOGICAL ADVANCEMENTS– MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
5.7.1 ADVANCED FORMULATION TECHNOLOGIES
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS
6.2 RESTRAINS
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS
6.3 OPPORTUNITIES
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS
6.3.2 PATENT CLIFF OF MAJOR DRUGS
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS
6.4 CHALLENGES
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG
7 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET, BY DRUG CLASS
7.1 OVERVIEW
7.2 ANTI-HYPERTENSIVE
7.2.1 DIURETICS
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS)
7.2.4 BETA BLOCKERS (BBS)
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS)
7.2.6 DIRECT VASODILATORS
7.2.7 ALPHA-1 BLOCKERS
7.2.8 CENTRAL ALPHA-2 AGONISTS
7.2.9 HORMONES
7.2.10 STEROID HORMONES
7.2.11 SEX HORMONES
7.2.12 ESTROGENS
7.2.13 PROGESTOGENS
7.2.14 ANDROGENS
7.2.15 THYROID HORMONES
7.2.16 OTHER HORMONES
7.3 ANTIMETABOLITES
7.3.1 PURINE ANALOGUES
7.3.2 PYRIMIDINE ANALOGUES
7.3.3 FOLATE ANTAGONISTS
7.4 LIPID LOWERING DRUGS
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS)
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS
7.4.3 FIBRATES
7.4.4 BILE ACID SEQUESTRANTS
7.4.5 PCSK9 INHIBITORS
7.5 ANTI-EPILEPTICS
7.6 ALKYLATING AGENTS
7.6.1 NITROGEN MUSTARDS
7.6.2 NITROSOUREAS
7.6.3 ALKYL SULFONATES
7.6.4 TRIAZENES
7.6.5 ETHYLENIMINES
7.7 ANTI-DEPRESSANTS
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.7.4 ATYPICAL ANTIDEPRESSANTS
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS)
7.7.6 NMDA RECEPTOR ANTAGONISTS
7.8 ANTI-PSYCHOTICS
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS
7.8.3 PHENOTHIAZINES
7.8.4 THIOXANTHENES
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS
7.9 OTHERS
8 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CARDIOVASCULAR DISEASES
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY
8.4 ONCOLOGY
8.5 DIABETES
8.6 NEUROLOGY
8.7 GASTROINTESTINAL DISEASES
8.8 DERMATOLOGY
8.9 OTHERS
9 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLEA
9.4 TOPICAL ADMINISTRATION
9.5 OTHERS
10 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 VALUE-ADDED BRANDED GENERICS
10.3 TRADE NAMED GENERICS
11 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOMECARE
12.5 ACADEMIC & RESEARCH INSTITUTES
12.6 OTHERS
13 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 RETAIL PHARMACIES
13.3 HOSPITAL PHARMACIES
13.4 DIRECT TENDERS
13.5 OTHERS
14 MIDDLE EAST AND AFRICA SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SAUDI ARABIA
14.1.2 UNITED ARAB EMIRATES
14.1.3 EGYPT
14.1.4 SOUTH AFRICA
14.1.5 ISRAEL
14.1.6 KUWAIT
14.1.7 BAHRAIN
14.1.8 QATAR
14.1.9 OMAN
14.1.10 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY LANDSCAPE
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 SANDOZ GROUP AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR.REDDY’S LABORATORIES LTD.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ALEMBIC PHARMACEUTICALS LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 AMNEAL PHARMACEUTICALS LLC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ASPEN HOLDINGS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOCON.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CIPLA
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 EMCURE PHARMACEUTICALS LIMITED
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ENDO, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 FRESENIUS SE & CO. KGAA
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 GLENMARK PHARMACEUTICALS LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 HIKMA PHARMACEUTICALS PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 INTAS PHARMACEUTICALS LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 LUPIN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 MANKIND PHARMA LIMITED
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 NATCO PHARMA LIMITED
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENTS
17.25 NEULAND LABORATORIES LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 ORCHIDPHARMA LTD.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 PANACEA BIOTEC
17.27.1 COMPANY SNAPSHOT
17.27.2 REVENUE ANALYSIS
17.27.3 PRODUCT PORTFOLIO
17.27.4 RECENT DEVELOPMENT
17.28 SAGENT
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 STRIDES PHARMA SCIENCE LIMITED.
17.29.1 COMPANY SNAPSHOT
17.29.2 REVENUE ANALYSIS
17.29.3 PRODUCT PORTFOLIO
17.29.4 RECENT DEVELOPMENT
17.3 TORRENT PHARMACEUTICALS LTD.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENTS
17.31 USV PRIVATE LIMITED.
17.31.1 COMPANY SNAPSHOT
17.31.2 SERVICE PORTFOLIO
17.31.3 RECENT DEVELOPMENT
17.32 WOCKHARDT LIMITED
17.32.1 COMPANY SNAPSHOT
17.32.2 REVENUE ANALYSIS
17.32.3 PRODUCT PORTFOLIO
17.32.4 RECENT DEVELOPMENT
17.33 MCKESSON CORPORATION
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENT
17.34 CENCORA, INC.
17.34.1 COMPANY SNAPSHOT
17.34.2 REVENUE ANALYSIS
17.34.3 PRODUCT PORTFOLIO
17.34.4 RECENT DEVELOPMENT
17.35 CARDINAL HEALTH
17.35.1 COMPANY SNAPSHOT
17.35.2 REVENUE ANALYSIS
17.35.3 PRODUCT PORTFOLIO
17.35.4 RECENT DEVELOPMENT
17.36 ALVOGEN
17.36.1 COMPANY SNAPSHOT
17.36.2 SERVICE PORTFOLIO
17.36.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
TABLE 2 PATENT LANDSCAPE
TABLE 3 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 81 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 83 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 85 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 87 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 MIDDLE EAST AND AFRICA VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 89 MIDDLE EAST AND AFRICA TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 90 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 91 MIDDLE EAST AND AFRICA ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 92 MIDDLE EAST AND AFRICA GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 93 MIDDLE EAST AND AFRICA PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 94 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 MIDDLE EAST AND AFRICA HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 96 MIDDLE EAST AND AFRICA CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 97 MIDDLE EAST AND AFRICA HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 98 MIDDLE EAST AND AFRICA ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 99 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 100 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 102 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 104 MIDDLE EAST AND AFRICA DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 105 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 106 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 107 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 108 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 MIDDLE EAST AND AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 MIDDLE EAST AND AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 MIDDLE EAST AND AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 MIDDLE EAST AND AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 MIDDLE EAST AND AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 MIDDLE EAST AND AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 MIDDLE EAST AND AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 MIDDLE EAST AND AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 MIDDLE EAST AND AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 MIDDLE EAST AND AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 MIDDLE EAST AND AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 MIDDLE EAST AND AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 MIDDLE EAST AND AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 MIDDLE EAST AND AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 MIDDLE EAST AND AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 MIDDLE EAST AND AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 MIDDLE EAST AND AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 MIDDLE EAST AND AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 MIDDLE EAST AND AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 MIDDLE EAST AND AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 MIDDLE EAST AND AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 MIDDLE EAST AND AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 MIDDLE EAST AND AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 MIDDLE EAST AND AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 MIDDLE EAST AND AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 MIDDLE EAST AND AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 MIDDLE EAST AND AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 MIDDLE EAST AND AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 MIDDLE EAST AND AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 MIDDLE EAST AND AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 MIDDLE EAST AND AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 MIDDLE EAST AND AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 MIDDLE EAST AND AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 MIDDLE EAST AND AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 156 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 MIDDLE EAST AND AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 MIDDLE EAST AND AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 167 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 172 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 173 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 SAUDI ARABIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 176 SAUDI ARABIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 SAUDI ARABIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 SAUDI ARABIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 SAUDI ARABIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 SAUDI ARABIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 SAUDI ARABIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 SAUDI ARABIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 SAUDI ARABIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 SAUDI ARABIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 SAUDI ARABIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 SAUDI ARABIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 SAUDI ARABIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 SAUDI ARABIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 SAUDI ARABIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 SAUDI ARABIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 SAUDI ARABIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 SAUDI ARABIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 SAUDI ARABIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 SAUDI ARABIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 SAUDI ARABIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 SAUDI ARABIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 SAUDI ARABIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 SAUDI ARABIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 SAUDI ARABIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 SAUDI ARABIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 SAUDI ARABIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 SAUDI ARABIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 SAUDI ARABIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 SAUDI ARABIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 SAUDI ARABIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 SAUDI ARABIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 SAUDI ARABIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 SAUDI ARABIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 SAUDI ARABIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 SAUDI ARABIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 SAUDI ARABIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 SAUDI ARABIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 SAUDI ARABIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 SAUDI ARABIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 SAUDI ARABIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 SAUDI ARABIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 SAUDI ARABIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 SAUDI ARABIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 SAUDI ARABIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 SAUDI ARABIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 SAUDI ARABIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SAUDI ARABIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 224 SAUDI ARABIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 SAUDI ARABIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 SAUDI ARABIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 SAUDI ARABIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 SAUDI ARABIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 SAUDI ARABIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 SAUDI ARABIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 SAUDI ARABIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 SAUDI ARABIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 SAUDI ARABIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 SAUDI ARABIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 235 SAUDI ARABIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 SAUDI ARABIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 SAUDI ARABIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 SAUDI ARABIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 SAUDI ARABIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 240 SAUDI ARABIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 241 SAUDI ARABIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 242 SAUDI ARABIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 UNITED ARAB EMIRATES ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 UNITED ARAB EMIRATES DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 UNITED ARAB EMIRATES ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 UNITED ARAB EMIRATES ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 UNITED ARAB EMIRATES BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 UNITED ARAB EMIRATES CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 UNITED ARAB EMIRATES DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 UNITED ARAB EMIRATES ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 UNITED ARAB EMIRATES CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 UNITED ARAB EMIRATES HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 UNITED ARAB EMIRATES STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 UNITED ARAB EMIRATES SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 UNITED ARAB EMIRATES ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 UNITED ARAB EMIRATES PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 UNITED ARAB EMIRATES ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 UNITED ARAB EMIRATES THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 UNITED ARAB EMIRATES OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 UNITED ARAB EMIRATES ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 UNITED ARAB EMIRATES PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 UNITED ARAB EMIRATES PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 UNITED ARAB EMIRATES FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 UNITED ARAB EMIRATES LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 UNITED ARAB EMIRATES STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 UNITED ARAB EMIRATES COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 UNITED ARAB EMIRATES FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 UNITED ARAB EMIRATES BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 UNITED ARAB EMIRATES PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 UNITED ARAB EMIRATES ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 UNITED ARAB EMIRATES ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 UNITED ARAB EMIRATES NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 UNITED ARAB EMIRATES NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 UNITED ARAB EMIRATES ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 UNITED ARAB EMIRATES TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 UNITED ARAB EMIRATES ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 UNITED ARAB EMIRATES ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 UNITED ARAB EMIRATES SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 UNITED ARAB EMIRATES SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 UNITED ARAB EMIRATES TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 UNITED ARAB EMIRATES ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 UNITED ARAB EMIRATES MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 UNITED ARAB EMIRATES NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 UNITED ARAB EMIRATES ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 UNITED ARAB EMIRATES SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 UNITED ARAB EMIRATES FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 UNITED ARAB EMIRATES PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 UNITED ARAB EMIRATES THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 UNITED ARAB EMIRATES NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 UNITED ARAB EMIRATES CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 UNITED ARAB EMIRATES PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 UNITED ARAB EMIRATES ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 UNITED ARAB EMIRATES SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 UNITED ARAB EMIRATES DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 UNITED ARAB EMIRATES NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 UNITED ARAB EMIRATES DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 UNITED ARAB EMIRATES OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 UNITED ARAB EMIRATES ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 UNITED ARAB EMIRATES INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 UNITED ARAB EMIRATES TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 308 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 310 UNITED ARAB EMIRATES RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 EGYPT BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 EGYPT ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 EGYPT DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 EGYPT ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 EGYPT ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 EGYPT BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 EGYPT CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 EGYPT DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 EGYPT ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 EGYPT CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 EGYPT HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 EGYPT STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 EGYPT SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 EGYPT ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 EGYPT PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 EGYPT ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 EGYPT THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 EGYPT OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 EGYPT ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 EGYPT PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 EGYPT PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 EGYPT FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 EGYPT LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 EGYPT STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 EGYPT COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 EGYPT FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 EGYPT BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 EGYPT PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 EGYPT ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 EGYPT ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 EGYPT NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 EGYPT NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 EGYPT ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 EGYPT TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 EGYPT ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 EGYPT ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 EGYPT SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 EGYPT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 EGYPT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 EGYPT ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 EGYPT MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 EGYPT NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 EGYPT ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 EGYPT SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 EGYPT FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 EGYPT PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 EGYPT THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 EGYPT NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 EGYPT BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 360 EGYPT CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 EGYPT PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 EGYPT ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 EGYPT SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 EGYPT HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 EGYPT DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 EGYPT NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 EGYPT GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 EGYPT DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 EGYPT OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 EGYPT BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 371 EGYPT ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 EGYPT INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 EGYPT TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 EGYPT BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 EGYPT BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 376 EGYPT BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 377 EGYPT BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 EGYPT RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 SOUTH AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 380 SOUTH AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 SOUTH AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 SOUTH AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 SOUTH AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 SOUTH AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 SOUTH AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 SOUTH AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 SOUTH AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 SOUTH AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 SOUTH AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 SOUTH AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 SOUTH AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SOUTH AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 SOUTH AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 SOUTH AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SOUTH AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 SOUTH AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 SOUTH AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 SOUTH AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 SOUTH AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SOUTH AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SOUTH AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 SOUTH AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SOUTH AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 SOUTH AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 SOUTH AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 SOUTH AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 SOUTH AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 SOUTH AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 SOUTH AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 SOUTH AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 SOUTH AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 SOUTH AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 SOUTH AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 SOUTH AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 SOUTH AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 SOUTH AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 SOUTH AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 SOUTH AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 SOUTH AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 SOUTH AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 SOUTH AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 SOUTH AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 SOUTH AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 SOUTH AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 SOUTH AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 SOUTH AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 428 SOUTH AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 SOUTH AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 SOUTH AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 SOUTH AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 SOUTH AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 433 SOUTH AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 SOUTH AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 SOUTH AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 SOUTH AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 SOUTH AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 SOUTH AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 439 SOUTH AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 SOUTH AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 SOUTH AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 SOUTH AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 SOUTH AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 444 SOUTH AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 445 SOUTH AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 446 SOUTH AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 ISRAEL BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 448 ISRAEL ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 ISRAEL DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 ISRAEL ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 ISRAEL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 ISRAEL BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 ISRAEL CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 ISRAEL DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 ISRAEL ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 ISRAEL CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 ISRAEL HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 ISRAEL STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 ISRAEL SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 ISRAEL ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 ISRAEL PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 ISRAEL ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 ISRAEL THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 ISRAEL OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 ISRAEL ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 ISRAEL PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 ISRAEL PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 ISRAEL FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 ISRAEL LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 ISRAEL STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 ISRAEL COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 ISRAEL FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 ISRAEL BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 ISRAEL PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 ISRAEL ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 ISRAEL ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 ISRAEL NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 ISRAEL NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 ISRAEL ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 ISRAEL TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 ISRAEL ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 ISRAEL ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 ISRAEL SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 ISRAEL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 ISRAEL TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 ISRAEL ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 ISRAEL MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 ISRAEL NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 ISRAEL ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 ISRAEL SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 491 ISRAEL FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 492 ISRAEL PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 ISRAEL THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 ISRAEL NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 ISRAEL BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 496 ISRAEL CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 ISRAEL PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 ISRAEL ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 499 ISRAEL SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 ISRAEL HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 ISRAEL DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 ISRAEL NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 ISRAEL GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 ISRAEL DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 ISRAEL OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 ISRAEL BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 507 ISRAEL ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 ISRAEL INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 ISRAEL TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 ISRAEL BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 ISRAEL BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 512 ISRAEL BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 513 ISRAEL BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 514 ISRAEL RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 KUWAIT BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 516 KUWAIT ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 KUWAIT DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 KUWAIT ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 KUWAIT ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 KUWAIT BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 KUWAIT CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 KUWAIT DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 KUWAIT ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 KUWAIT CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 KUWAIT HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 KUWAIT STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 KUWAIT SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 KUWAIT ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 KUWAIT PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 KUWAIT ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 KUWAIT THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 KUWAIT OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 KUWAIT ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 KUWAIT PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 KUWAIT PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 KUWAIT FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 KUWAIT LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 KUWAIT STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 KUWAIT COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 KUWAIT FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 KUWAIT BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 KUWAIT PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 KUWAIT ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 KUWAIT ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 KUWAIT NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 KUWAIT NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 KUWAIT ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 KUWAIT TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 KUWAIT ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 KUWAIT ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 KUWAIT SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 KUWAIT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 KUWAIT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 KUWAIT ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 KUWAIT MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 KUWAIT NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 KUWAIT ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 KUWAIT SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 KUWAIT FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 KUWAIT PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 KUWAIT THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 KUWAIT NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 KUWAIT BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 564 KUWAIT CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 KUWAIT PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 KUWAIT ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 KUWAIT SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 KUWAIT HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 KUWAIT DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 KUWAIT NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 KUWAIT GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 KUWAIT DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 KUWAIT OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 KUWAIT BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 575 KUWAIT ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 KUWAIT INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 KUWAIT TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 KUWAIT BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 KUWAIT BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 580 KUWAIT BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 581 KUWAIT BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 582 KUWAIT RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 BAHRAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 584 BAHRAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 BAHRAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 BAHRAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 BAHRAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 BAHRAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 BAHRAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 BAHRAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 BAHRAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 BAHRAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 BAHRAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 BAHRAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 BAHRAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 BAHRAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 BAHRAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 BAHRAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 BAHRAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 BAHRAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 BAHRAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 BAHRAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 BAHRAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 BAHRAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 BAHRAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 BAHRAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 BAHRAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 BAHRAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 BAHRAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 BAHRAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 BAHRAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 BAHRAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 BAHRAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 BAHRAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 BAHRAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 BAHRAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 BAHRAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 BAHRAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 BAHRAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 BAHRAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 BAHRAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 BAHRAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 BAHRAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 BAHRAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 BAHRAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 BAHRAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 BAHRAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 628 BAHRAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 BAHRAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 BAHRAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 BAHRAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 632 BAHRAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 BAHRAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 BAHRAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 BAHRAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 BAHRAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 BAHRAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 BAHRAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 BAHRAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 BAHRAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 BAHRAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 BAHRAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 643 BAHRAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 BAHRAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 BAHRAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 BAHRAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 647 BAHRAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 648 BAHRAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 BAHRAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 650 BAHRAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 QATAR BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 652 QATAR ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 QATAR DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 QATAR ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 QATAR ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 QATAR BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 QATAR CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 QATAR DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 QATAR ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 QATAR CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 QATAR HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 QATAR STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 QATAR SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 QATAR ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 QATAR PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 QATAR ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 QATAR THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 668 QATAR OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 QATAR ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 QATAR PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 QATAR PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 QATAR FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 QATAR LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 QATAR STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 QATAR COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 QATAR FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 QATAR BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 QATAR PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 QATAR ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 QATAR ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 QATAR NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 QATAR NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 QATAR ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 QATAR TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 QATAR ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 QATAR ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 QATAR SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 QATAR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 QATAR TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 QATAR ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 691 QATAR MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 QATAR NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 QATAR ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 694 QATAR SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 695 QATAR FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 QATAR PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 QATAR THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 698 QATAR NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 QATAR BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 700 QATAR CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 QATAR PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 QATAR ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 QATAR SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 QATAR HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 QATAR DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 QATAR NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 QATAR GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 QATAR DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 QATAR OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 QATAR BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 711 QATAR ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 QATAR INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 QATAR TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 QATAR BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 QATAR BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 716 QATAR BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 717 QATAR BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 718 QATAR RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 OMAN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 720 OMAN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 721 OMAN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 OMAN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 OMAN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 OMAN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 OMAN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 OMAN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 OMAN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 OMAN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 OMAN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 OMAN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 OMAN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 OMAN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 OMAN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 734 OMAN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 OMAN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 736 OMAN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 OMAN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 OMAN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 OMAN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 OMAN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 OMAN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 742 OMAN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 OMAN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 OMAN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 OMAN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 OMAN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 OMAN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 OMAN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 OMAN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 OMAN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 OMAN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 OMAN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 OMAN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 OMAN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 OMAN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 OMAN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 OMAN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 OMAN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 OMAN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 OMAN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 OMAN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 OMAN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 OMAN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 764 OMAN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 OMAN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 OMAN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 OMAN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 768 OMAN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 OMAN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 OMAN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 OMAN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 OMAN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 OMAN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 OMAN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 OMAN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 OMAN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 OMAN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 OMAN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 779 OMAN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 780 OMAN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 781 OMAN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 782 OMAN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 783 OMAN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 784 OMAN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 785 OMAN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 OMAN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 REST OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EXECUTIVE SUMMARY
FIGURE 10 STRATEGIC DECISIONS
FIGURE 11 NINE SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS (2024)
FIGURE 12 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET IN 2025 & 2032
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
FIGURE 16 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2024
FIGURE 17 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)
FIGURE 19 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, 2024
FIGURE 21 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 23 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 25 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 27 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024
FIGURE 29 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)
FIGURE 31 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024
FIGURE 33 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)
FIGURE 35 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, 2024
FIGURE 37 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 39 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 41 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 42 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 43 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SNAPSHOT (2024)
FIGURE 45 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
